Aimmune Therapeutics, Inc. (AIMT) Upgraded by Zacks Investment Research to Hold

Zacks Investment Research upgraded shares of Aimmune Therapeutics, Inc. (NASDAQ:AIMT) from a sell rating to a hold rating in a report issued on Monday morning.

According to Zacks, “Aimmune Therapeutics, Inc. is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies. The Company’s characterized oral desensitization immunotherapy includes AR101, a product for the treatment of peanut allergy in children and adults which is in clinical trial stage. Aimmune Therapeutics, Inc. is headquartered in Brisbane, California. “

Several other research analysts also recently commented on the company. Piper Jaffray Companies set a $38.00 target price on Aimmune Therapeutics and gave the stock a buy rating in a research note on Thursday, July 27th. Wedbush reiterated an outperform rating and set a $42.00 target price on shares of Aimmune Therapeutics in a research note on Monday, July 24th. Finally, BidaskClub downgraded Aimmune Therapeutics from a hold rating to a sell rating in a research note on Friday, August 11th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and one has assigned a buy rating to the company’s stock. Aimmune Therapeutics presently has a consensus rating of Hold and an average price target of $40.00.

Aimmune Therapeutics (NASDAQ:AIMT) opened at 25.90 on Monday. Aimmune Therapeutics has a one year low of $14.87 and a one year high of $27.31. The firm’s market capitalization is $1.31 billion. The stock’s 50 day moving average price is $24.54 and its 200-day moving average price is $24.54.

Aimmune Therapeutics (NASDAQ:AIMT) last posted its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.65) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.64) by ($0.01). On average, equities research analysts expect that Aimmune Therapeutics will post ($2.71) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This story was published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this story on another site, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this story can be viewed at https://ledgergazette.com/2017/10/17/aimmune-therapeutics-inc-aimt-upgraded-by-zacks-investment-research-to-hold.html.

In other Aimmune Therapeutics news, insider Susan E. Barrowcliffe sold 6,110 shares of Aimmune Therapeutics stock in a transaction on Tuesday, July 25th. The stock was sold at an average price of $22.00, for a total value of $134,420.00. Following the completion of the transaction, the insider now directly owns 960 shares of the company’s stock, valued at approximately $21,120. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Stephen George Dilly sold 100,000 shares of Aimmune Therapeutics stock in a transaction on Monday, September 25th. The shares were sold at an average price of $25.01, for a total value of $2,501,000.00. The disclosure for this sale can be found here. Insiders sold a total of 331,306 shares of company stock valued at $8,053,785 over the last ninety days. Insiders own 24.56% of the company’s stock.

A number of hedge funds and other institutional investors have recently made changes to their positions in AIMT. Nationwide Fund Advisors raised its holdings in Aimmune Therapeutics by 23.7% in the 1st quarter. Nationwide Fund Advisors now owns 20,095 shares of the biotechnology company’s stock valued at $437,000 after acquiring an additional 3,851 shares in the last quarter. Swiss National Bank raised its holdings in Aimmune Therapeutics by 17.5% in the 1st quarter. Swiss National Bank now owns 36,974 shares of the biotechnology company’s stock valued at $803,000 after acquiring an additional 5,500 shares in the last quarter. Victory Capital Management Inc. acquired a new position in Aimmune Therapeutics in the 1st quarter valued at $1,064,000. American International Group Inc. raised its holdings in Aimmune Therapeutics by 7.1% in the 1st quarter. American International Group Inc. now owns 16,184 shares of the biotechnology company’s stock valued at $352,000 after acquiring an additional 1,070 shares in the last quarter. Finally, Wellington Management Group LLP raised its holdings in Aimmune Therapeutics by 641.2% in the 1st quarter. Wellington Management Group LLP now owns 2,316,553 shares of the biotechnology company’s stock valued at $50,339,000 after acquiring an additional 2,004,023 shares in the last quarter. 72.90% of the stock is owned by hedge funds and other institutional investors.

Aimmune Therapeutics Company Profile

Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, whic

According to Zacks, “Aimmune Therapeutics, Inc. is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies. The Company’s characterized oral desensitization immunotherapy includes AR101, a product for the treatment of peanut allergy in children and adults which is in clinical trial stage. Aimmune Therapeutics, Inc. is headquartered in Brisbane, California. “

Several other research analysts also recently commented on the company. Piper Jaffray Companies set a $38.00 target price on Aimmune Therapeutics and gave the stock a buy rating in a research note on Thursday, July 27th. Wedbush reiterated an outperform rating and set a $42.00 target price on shares of Aimmune Therapeutics in a research note on Monday, July 24th. Finally, BidaskClub downgraded Aimmune Therapeutics from a hold rating to a sell rating in a research note on Friday, August 11th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and one has assigned a buy rating to the company’s stock. Aimmune Therapeutics presently has a consensus rating of Hold and an average price target of $40.00.

Aimmune Therapeutics (NASDAQ:AIMT) opened at 25.90 on Monday. Aimmune Therapeutics has a one year low of $14.87 and a one year high of $27.31. The firm’s market capitalization is $1.31 billion. The stock’s 50 day moving average price is $24.54 and its 200-day moving average price is $24.54.

Aimmune Therapeutics (NASDAQ:AIMT) last posted its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.65) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.64) by ($0.01). On average, equities research analysts expect that Aimmune Therapeutics will post ($2.71) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This story was published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this story on another site, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this story can be viewed at https://ledgergazette.com/2017/10/17/aimmune-therapeutics-inc-aimt-upgraded-by-zacks-investment-research-to-hold.html.

In other Aimmune Therapeutics news, insider Susan E. Barrowcliffe sold 6,110 shares of Aimmune Therapeutics stock in a transaction on Tuesday, July 25th. The stock was sold at an average price of $22.00, for a total value of $134,420.00. Following the completion of the transaction, the insider now directly owns 960 shares of the company’s stock, valued at approximately $21,120. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Stephen George Dilly sold 100,000 shares of Aimmune Therapeutics stock in a transaction on Monday, September 25th. The shares were sold at an average price of $25.01, for a total value of $2,501,000.00. The disclosure for this sale can be found here. Insiders sold a total of 331,306 shares of company stock valued at $8,053,785 over the last ninety days. Insiders own 24.56% of the company’s stock.

A number of hedge funds and other institutional investors have recently made changes to their positions in AIMT. Nationwide Fund Advisors raised its holdings in Aimmune Therapeutics by 23.7% in the 1st quarter. Nationwide Fund Advisors now owns 20,095 shares of the biotechnology company’s stock valued at $437,000 after acquiring an additional 3,851 shares in the last quarter. Swiss National Bank raised its holdings in Aimmune Therapeutics by 17.5% in the 1st quarter. Swiss National Bank now owns 36,974 shares of the biotechnology company’s stock valued at $803,000 after acquiring an additional 5,500 shares in the last quarter. Victory Capital Management Inc. acquired a new position in Aimmune Therapeutics in the 1st quarter valued at $1,064,000. American International Group Inc. raised its holdings in Aimmune Therapeutics by 7.1% in the 1st quarter. American International Group Inc. now owns 16,184 shares of the biotechnology company’s stock valued at $352,000 after acquiring an additional 1,070 shares in the last quarter. Finally, Wellington Management Group LLP raised its holdings in Aimmune Therapeutics by 641.2% in the 1st quarter. Wellington Management Group LLP now owns 2,316,553 shares of the biotechnology company’s stock valued at $50,339,000 after acquiring an additional 2,004,023 shares in the last quarter. 72.90% of the stock is owned by hedge funds and other institutional investors.

Aimmune Therapeutics Company Profile

Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Receive News & Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply